Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -96.57% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.78%.
RETURN ON ASSETS (ROA)
-96.57%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
-214.05%
vs the sector median at left
Mobia Medical, Inc. Common Stock
Market Cap
$308.22M
Return on Assets (ROA)
-96.57%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$304.21M
Return on Assets (ROA)
-24.94%
TTM Avg
-31.51%
3Y Avg
-135.72%
5Y Avg
-152.11%
Market Cap
$320.64M
Return on Assets (ROA)
-28.22%
TTM Avg
-29.68%
3Y Avg
-31.08%
5Y Avg
-26.24%
Market Cap
$321.44M
Return on Assets (ROA)
-90.17%
TTM Avg
-81.88%
3Y Avg
-55.65%
5Y Avg
-44.24%
Market Cap
$295.55M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$322.92M
Return on Assets (ROA)
-160.64%
TTM Avg
-128.90%
3Y Avg
-103.44%
5Y Avg
-103.44%
Market Cap
$287.88M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$327.34M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
Market Cap
$288.21M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $308.22M | -96.57% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $304.21M | -24.94% | -31.51% | -135.72% | -152.11% |
| C4 Therapeutics, Inc. (CCCC)vs › | $320.64M | -28.22% | -29.68% | -31.08% | -26.24% |
| Avita Medical Inc. (RCEL)vs › | $321.44M | -90.17% | -81.88% | -55.65% | -44.24% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.55M | -104.42% | -76.93% | -55.08% | -54.19% |
| CapsoVision, Inc. (CV)vs › | $322.92M | -160.64% | -128.90% | -103.44% | -103.44% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.88M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $327.34M | -39.85% | -37.20% | -38.95% | -33.46% |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.21M | -35.03% | -13.04% | -43.14% | -55.84% |
| Standard BioTools Inc. (LAB)vs › | $286.63M | -13.93% | -17.93% | -26.92% | -24.25% |
ROA
-96.6%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -96.57% |
